Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents

Trial Profile

Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daclatasvir/sofosbuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Peginterferon (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary) ; Sofosbuvir (Primary) ; Antivirals
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms ANRSCO23CUPILT
  • Most Recent Events

    • 05 Aug 2019 Results (n=67) assessing the changes to blood concentrations of Cyclosporine or Tacrolimus and to rule out any drug-drug interactions during SOF/DCV-based antiviral therapy in liver transplant recipients published in the European Journal of Clinical Pharmacology
    • 27 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 17 Apr 2018 Results (n=139) assessing safety of sofosbuvir regimens after liver transplantation longitudinal assessment of renal function, were published in the Alimentary Pharmacology and Therapeutics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top